Sanofi: Press Releases, Monday, December 9, 2019

Sanofi CEO unveils new strategy to drive innovation and growth

  • Prioritize key growth drivers – Dupixent® (dupilumab) and vaccines
  • Accelerate R&D focus on six potentially transformative medicines
  • Improve operating efficiencies to fund growth and expand business operating income margin1
  • Align to support new strategy with three core businesses and a standalone Consumer Healthcare unit

PARIS – DECEMBER 9, 2019 – At Sanofi’s Capital Markets Day tomorrow with the financial community, the company will provide details of a new strategic framework with four key priorities to drive innovation and growth. Sanofi will also discuss the alignment of the organization to support this new strategy.

Sanofi Chief Executive Officer Paul Hudson and Executive Committee members will provide a detailed overview of the company’s strategy based on four main priorities – focusing the portfolio, leading with science, accelerating efficiency, and reinventing how the company works.

“Our new strategy positions Sanofi to achieve breakthroughs with our most promising medicines, addressing significant patient needs. We will anchor our efforts in leading-edge science with clearer priorities and a focus on delivering results,”said Hudson. “Sanofi gained leadership and changed the practice of medicine in diabetes and cardiovascular diseases. We are now preparing for our next cycle, with a new round of innovative solutions for patients. I’m confident we will achieve long-term growth and value for shareholders while turning innovation into transformative medicines for patients.”

Focus on growth

  • Dupixent® (dupilumab)2 – Sanofi expects to deliver strong growth for Dupixent with the ambition of achieving more than €10 billion in peak sales driven by its unique mechanism of action targeting the type 2 inflammation pathway.
  • Vaccines – Vaccines are expected to deliver a mid-to-high single-digit net sales CAGR from 2018 to 2025, through differentiated products, market expansion and new launches.
  • Pipeline – The company has identified and prioritized six potentially transformative therapies.

Additional core drivers include treatments for oncology, hematology, rare diseases, neurology, and Sanofi’s strong presence in China.

1 2 3 4 5 6 7 8 9 10 11 12 13